F. S. Wehweck

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

This study examines PD-L1 and PD-1 expression in soft tissue sarcomas and finds associations with TILs and poor clinical outcomes, supporting immune checkpoint inhibition in PD-L1-positive cases.

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.